Investigational agents in metastatic basal cell carcinoma: focus on vismodegib.

Mutations affecting segment number and polarity in Drosophila. Nature (1980) 18.72

Hedgehog signaling in animal development: paradigms and principles. Genes Dev (2001) 14.75

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23

Sonic hedgehog signaling is essential for hair development. Curr Biol (1998) 5.58

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40

Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov (2006) 5.30

The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet (1996) 4.36

Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A (2007) 4.15

Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling. Development (1999) 4.06

Basal-cell carcinoma. N Engl J Med (2005) 4.05

Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 4.05

Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci (2009) 3.74

Sonic hedgehog signaling regulates Gli2 transcriptional activity by suppressing its processing and degradation. Mol Cell Biol (2006) 3.29

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med (2010) 2.86

Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat Genet (2000) 2.82

Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res (2010) 2.45

Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell (2008) 2.42

Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc Natl Acad Sci U S A (2009) 2.41

Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res (2011) 2.12

Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol (2011) 1.98

Prevalence of a history of skin cancer in 2007: results of an incidence-based model. Arch Dermatol (2010) 1.92

Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res (2011) 1.72

Disruption of sonic hedgehog signaling alters growth and patterning of lingual taste papillae. Dev Biol (2003) 1.69

Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev (2004) 1.58

Targeting the Hedgehog pathway in cancer. Ther Adv Med Oncol (2010) 1.35

Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 1.25

Molecular pathways: the role of primary cilia in cancer progression and therapeutics with a focus on Hedgehog signaling. Clin Cancer Res (2012) 1.20

Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction-liquid chromatographic-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 1.20

Naturally occurring small-molecule inhibitors of hedgehog/GLI-mediated transcription. Chembiochem (2008) 1.14

Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Clin Cancer Res (2011) 1.10

Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449). J Med Chem (2011) 1.03

A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos (2011) 1.02

A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists. Mol Cancer Ther (2011) 0.91

Antitumoral effects of calcitriol in basal cell carcinomas involve inhibition of hedgehog signaling and induction of vitamin D receptor signaling and differentiation. Mol Cancer Ther (2011) 0.88

Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest (2006) 0.84

Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol (1999) 0.81